Effect of AF, olaparib and aurola treatment on immune-related

Frontiers The potential of PARP inhibitors in targeted cancer therapy and immunotherapy

Elly MARCQ, Postdoctoral Researcher, Doctor of Medicine

Frontiers The potential of PARP inhibitors in targeted cancer therapy and immunotherapy

Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review - ScienceDirect

Breast cancer heterogeneity and its implication in personalized precision therapy, Experimental Hematology & Oncology

An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic

Effect of AF, olaparib and aurola treatment on immune-related

Frontiers Preclinical Studies Comparing Efficacy and Toxicity of DNA Repair Inhibitors, Olaparib, and AsiDNA, in the Treatment of Carboplatin-Resistant Tumors

beta Actin Polyclonal Antibody (20536-1-AP)